November 7, 2013 – Abbott announced clinically meaningful changes to quality of life, a reduction in rehospitalization ...
November 4, 2013 — New trial data showed clinically meaningful changes to quality of life, a reduction in ...
October 31, 2013 — Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate ...
October 29, 2013 — Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to ...
This animation, provided by Abbott Vascular, demonstrates how the U.S. Food and Drug Administration (FDA)-cleared ...
October 25, 2013 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the MitraClip, the first ...
October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to ...
September 20, 2013— The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing ...
There is no shortage of debate among interventional cardiologists over whether vascular closure devices should be used ...
Vascular closure devices (VCD) were first introduced in the early 1990s with a goal to achieve quick hemostasis, thus ...